Skip to main content

Weather Alert

Hurricane activity is severely impacting Quest locations across the Southeast. We ask that patients please double check your appointment status to ensure your designated Patient Service Center is operational.

Hide
Quest Diagnostics

The Proportion of Reportable cfDNA Screening Results for Fetal Aneuploidy in Pregnancies Less Than 10 Weeks Gestation

2023 National Society of Genetic Counselors (NSGC) Conference

NSGC 2023

Chicago, IL, October 17-21, 2023

Poster presentation: The proportion of reportable cfDNA screening results for fetal aneuploidy in pregnancies less than 10 weeks gestation

Authors: Niemchak T, Wilkinson J, Anderson B

Specialty: Genetics, Women's Health

Related content

Publication
Prenatal Diagnosis of Diencephalic-Mesencephalic Junction Dysplasia: Fetal Magnetic Resonance Imaging Phenotypes, Genetic Diagnoses, and Outcomes
Publication
Novel CTNNB1 Variant Leading to Neurodevelopmental Disorder with Spastic Diplegia and Visual Defects Plus Peripheral Neuropathy: A Case Report
Test FAQ
Chromosome Analysis, POC Tissue
Test FAQ
Maternal Serum AFP

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.